Skip to Main content Skip to Navigation
Preprints, Working Papers, ...

Nebulized fusion inhibitory peptide protects cynomolgus macaques from measles virus infection

Abstract : Abstract Measles is the most contagious airborne viral infection and the leading cause of child death among vaccine-preventable diseases. We show here that aerosolized lipopeptide fusion inhibitors, derived from heptad-repeat regions of the measles virus (MeV) fusion protein, block respiratory MeV infection in a non-human primate model, the cynomolgus macaque. We used a custom-designed mesh nebulizer to ensure efficient aerosol delivery of peptides to the respiratory tract and demonstrated the absence of adverse effects and lung pathology in macaques. The nebulized peptide efficiently prevented MeV infection, resulting in the complete absence of MeV RNA, MeV-infected cells, and MeV-specific humoral responses in treated animals. This strategy provides an additional shield which complements vaccination to fight against respiratory infection, presenting a proof-of-concept for the aerosol delivery of fusion inhibitory peptides to protect against measles and other airborne viruses, including SARS-CoV-2, in case of high-risk exposure, that can be readily translated to human trials.
Complete list of metadata
Contributor : Cyrille Mathieu Connect in order to contact the contributor
Submitted on : Wednesday, September 14, 2022 - 12:17:07 PM
Last modification on : Saturday, September 24, 2022 - 3:10:05 PM




Olivier Reynard, Claudia Gonzalez, Claire Dumont, Mathieu Iampietro, Marion Ferren, et al.. Nebulized fusion inhibitory peptide protects cynomolgus macaques from measles virus infection. 2022. ⟨hal-03777084⟩



Record views